Coyne 2000.

Methods	Study design: parallel RCT Study duration: NS Duration of follow‐up: 20 weeks
Participants	Country: USA Setting: multicentre Dialysis patients; no rHuEPO in previous 12 weeks; baseline Hb ≤ 10.0 g/dL Number: treatment group 1 (90); treatment group 2 (31) Mean age ± SD (years): NS M/F: NS Exclusion criteria: NS
Interventions	Treatment group 1 DA: 0.45 µg/kg IV or SC once/wk, continued for 20 weeks Treatment group 2 rHuEPO: 50 U/kg 3 times/wk (150 U/kg/wk), continued for 20 weeks Other information Dose adjustments made as necessary to achieve target Hb Co‐interventions NS
Outcomes	% achieving target Hb Adverse events
Notes	Loss to follow‐up: no information about any losses to follow‐up or patients excluded from analyses Additional data requested from author and information on randomisation was obtained Abstract only
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	"Randomization was centrally performed using an IVRS system" (information from author)
Allocation concealment (selection bias)	Low risk	"Randomization was centrally performed using an IVRS system" (information from author)
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Primary outcome was laboratory based and not likely to be influenced by blinding
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Primary outcome was laboratory based and not likely to be influenced by blinding
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	NR; data provided as % and unclear whether all patients completed study
Selective reporting (reporting bias)	Unclear risk	Abstract only, not all results available
Other bias	Unclear risk	NS